Avadel Pharmaceuticals Plc
(NASDAQ: AVDL)
|
4:00 PM EST, 11/30/23 | |||
---|---|---|---|---|
Last: $11.54 | Change: +0.13 | %Change: +1.14% | Volume: 291,752 |
Open: | $ 11.43 | Volume: | 291,752 | |
---|---|---|---|---|
High: | $ 11.70 | Yield(%) | 0.00 | |
Low: | $ 11.41 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 1.02B | |
EPS ($) | -2.16 | Shares Out: | 89.40M |
% Price Change (last 4 weeks): | 10.56 |
---|---|
% Price Change (last 13 weeks): | -17.85 |
% Price Change (last 26 weeks): | -17.62 |
% Price Change (last 52 weeks): | 24.43 |
% Price Change (year to date): | 59.36 |
Return on Equity (%): | -481.49 |
---|---|
Return on Assets (%): | -60.91 |
Return on Invested Capital (%): | -48.91 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $10.76 |
---|---|
200-day Moving Average: | $12.00 |
Avg. Daily Vol. (last 50 days): | 612,392 |
Avg. Daily Vol. (last 200 days): | 756,730 |
52-wk high: | $16.85 |
52-wk low: | $5.92 |
Bid: | $10.74 |
Ask: | $12.00 |
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.
|
Avadel Pharmaceuticals Plc
10 Earlsfort Terrace Dublin DU 02 Phone: 353.1.901.5201 Fax: n/a http://www.avadel.com |
Earnings (1year) ($): | -2.16 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -0.33 |
Cash Flow ($): | n/a |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.81 |
---|---|
Current Ratio (x): | 1.81 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |